[Management of systemic lupus erythematosus].
In the last few decades a number of small, often largely unrecognized steps have fundamentally changed the management of systemic lupus erythematosus (SLE). The current goal is to stop all disease activity without long-term use of more than 5 mg prednisolone per day. Remission, i.e. absence of activity in the SLE activity score of choice, is the defined target in the treat to target approach. The essential basic measures include life-long hydroxychloroquine as well as protection from sunlight (UV) and vitamin D substitution. Patients suffering from SLE need more vaccinations than the healthy population and control of risk factors for atherosclerosis is critical for long-term survival. Methotrexate is on par with azathioprine. If disease activity cannot be controlled in this way, belimumab is an approved therapeutic option. Cyclophosphamide is still used but only in life-threatening situations, such as lupus nephritis or central nervous system (CNS) vasculitis and in drastically reduced doses. Alternatively, off-label mycophenolate mofetil (MMF) can be used particularly for lupus nephritis and off-label rituximab in refractory disease courses. Numerous novel approaches are being tested in controlled trials and it is hoped that new drugs will be available for SLE patients within a few years.
Bereich Rheumatologie, Medizinische Klinik und Poliklinik III, Universitätsklinikum und Medizinische Fakultät Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. martin.aringer@uniklinikum-dresden.de.
M
M
Aringer
Poliklinik und Funktionsbereich für Rheumatologie, Hiller Forschungszentrum Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland.
M
M
Schneider
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D006886:Hydroxychloroquine / Q000008:administration & dosage*; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis* / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage*; D010346:Patient Care Management / Q000379:methods; D010347:Patient Care Planning; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D006886:Hydroxychloroquine; D008727:Methotrexate
Antimalarials; Azathioprine; Glucocorticoids; Lupus nephritis; Methotrexate
Ann Rheum Dis. 2014 Jan;73(1):17-23
24126457
Autoimmun Rev. 2016 Feb;15(2):198-201
26588998
Z Rheumatol. 2014 Aug;73(6):496-500
24577490
Ann Rheum Dis. 2012 Nov;71(11):1771-82
22851469
Lupus. 2016 Jul;25(8):805-11
27252256
Rheumatology (Oxford). 2013 Dec;52(12):2292-301
24049101
Ann Rheum Dis. 2010 Dec;69(12):2074-82
20724309